Print this page
{radonc}
-
A Phase I Study to Evaluate the Safety of Colchicine for Treatment and Prevention of Radiation-Induced Dermatitis.
Protocol: 032112Principal Investigator:
-
Bruce Haffty MD
Applicable Disease Sites: Lip, Oral Cavity and Pharynx -
A Phase II Randomized Pilot Study Comparing High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy in Localized Prostate Cancer.
Protocol: 081805Principal Investigator:
-
Lara Hathout MD
Applicable Disease Sites: Prostate -
The Role of Adaptive Radiation Planning in Patients with Non-Small Cell Lung Cancer on Radiation Induced Toxicity .
Protocol: 032009Principal Investigator:
-
Salma Jabbour M.D.
Applicable Disease Sites: Lung -
A Phase II Trial of Tislelizumab Consolidation after Liver-Directed Therapy for Hepatocellular Carcinoma.
Protocol: 072105Principal Investigator:
-
Salma Jabbour M.D.
Applicable Disease Sites: Liver -
Preoperative ChemoRadiation and FOLFOXIRI To Escalate Complete Response for Rectal Cancer.
Protocol: 072202Principal Investigator:
-
Salma Jabbour M.D.
Applicable Disease Sites: Rectum -
A Phase 1/Ia Trial of AN0025 with Chemoradiation Therapy in Stage III NSCLC Patients.
Protocol: 032303Principal Investigator:
-
Salma Jabbour M.D.
Applicable Disease Sites: Lung -
A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies.
Protocol: 052002Principal Investigator:
-
Salma Jabbour M.D.
Applicable Disease Sites: Liver
Any Site
Other Digestive Organ -
NRG-GU012: Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Study (SAMURAI)
Protocol: 082305Principal Investigator:
-
Lara Hathout MD
Applicable Disease Sites: Kidney -
CTEP #10512: A Phase 2 Randomized Study of the BER Inhibitor TRC102 in Combination with Standard Pemetrexed-Platinum-Radiation in Stage III Non-Squamous Non-Small Cell Lung Cancer
Protocol: 032309Principal Investigator:
-
Salma Jabbour M.D.
Applicable Disease Sites: Lung -
Randomized Phase III Trial Incorporating Abiraterone Acetate With Prednisone and Apalutamide and Advanced Imaging Into Salvage Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy.
Protocol: 082003Principal Investigator:
-
Lara Hathout MD
Applicable Disease Sites: Prostate -
Open-Label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab with Pembrolizumab) in Combination with Concurrent Chemoradiotherapy followed by MK-7684A Versus Concurrent Chemoradiotherapy followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage III NSCLC.
Protocol: 032205Principal Investigator:
-
Salma Jabbour M.D.
Applicable Disease Sites: Lung -
Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification And Intensification Clinical Trial Evaluation.
Protocol: 082201Principal Investigator:
-
Lara Hathout MD
Applicable Disease Sites: Prostate -
Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated with Chemoradiation Therapy: A Prospective Longitudinal Cohort.
Protocol: 152101Principal Investigator:
-
Salma Jabbour M.D.
Applicable Disease Sites: Lung -
The Radiation Oncology-Biology Integration Network (ROBIN) Molecular Characterization Trial (MCT) of Standard Short Course Radiotherapy for Rectal Cancer.
Protocol: 152301Principal Investigator:
-
Salma Jabbour M.D.
Applicable Disease Sites: Rectum